07

Jul

2020

17:00

BST

Webinar

Emerging Evidence in Left Atrial Appendage Occlusion vs. Oral Anticoagulation Therapy with NOAC

Average (ratings)
No ratings
Your rating

Overview

Transcatheter left atrial appendage occlusion (LAAO) is proven non-inferior to warfarin in atrial fibrillation (AF). However, novel oral anticoagulation (NOAC) is now preferred over warfarin as thromboprophylaxis in AF. This study sought to investigate clinical outcome and prognosis in patients with AF treated with either LAAO or NOAC.

Based on the global prospective Amulet Observational Registry (n=1,088), the faculty performed a follow-up study using propensity score 1:2 matching with replacement. A group of 18,570 patients with incident AF and treatment with NOAC (time period 2013-2015) was identified through the Danish National Patient Registry and the Danish National Prescription Registry.

The primary outcome was a composite of ischemic stroke, systemic embolism, major bleeding and all-cause mortality. Secondary outcomes were the individual endpoints of ischemic stroke, major bleeding and all-cause mortality. Both cohorts included the analysis for 2 years of follow-up.

Here, the study author and panelists discuss the findings and wider implications for clinical practice in further detail.

Faculty:


Jens Erik Nielsen Kudsk

Jens Erik Nielsen Kudsk


A John Camm

A John Camm


Vivek Reddy

Vivek Reddy

This webinar is supported by

Learning Objectives

  • Review of study results. What does the latest data tell us?
  • Discussion on study importance and why this information is important?
  • Discussion on clinical insights & impact for future LAAO vs NOAC drug studies
  • Outlook for global CATALYST trial evaluating safety and effectiveness of Amulet compared to NOAC therapy

Audience

  • Interventional Cardiologists implanting LAAO devices
  • Electrophysiologists implanting LAAO devices
  • Stroke specialists: Neurologists, General Cardiologists managing high risk ischemic stroke patients
  • Gastroenterologists managing patients who have had or at high risk for bleeding from oral anticoagulant therapy
  • Nephrologists managing patients who have had or at high risk for bleeding from oral anticoagulant therapy

Faculty Biographies


Jens Erik Nielsen Kudsk

Jens Erik Nielsen Kudsk

Jens Erik Nielsen Kudsk is a Professor of Cardiology and Head of Structural Heart Interventions at Aarhus University Hospital, Denmark.

View full profile

A John Camm

A John Camm

John Camm is British Heart Foundation Professor of Clinical Cardiology (Emeritus) at St George’s University of London, London, UK. His interests include cardiac arrhythmias, atrial fibrillation, stroke prevention, and anticoagulation.

View full profile

Vivek Reddy

Vivek Reddy

Dr Vivek Y. Reddy is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Director of Electrophysiology for the Mount Sinai Health System, and The Leona M. and Harry B.

View full profile